Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
VioQuest Pharmaceuticals
VioQuest Pharmaceuticals Presents Phase 1 Data Showing Promising Immune Response and Safety Profile of Lenocta
June 17th, 2008
VioQuest Pharmaceuticals (OTCBB: VOQP) reported updated data from a Phase 1 dose escalation study evaluating Lenocta(TM) (sodium stibogluconate) in combination with interferon alpha-2b (IFN alpha-2b) in patients with various advanced solid tumors. Data from 21 patients were presented during an oral session titled "Developmental Therapeutics: Immunotherapy," by Aung Naing, MD, assistant professor of medicine at the University of Texas M.D. Anderson Cancer Center, at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. "To date, single-agent immune-based strategies have shown limited promise for treating well-established tumors or advanced...
Source: Cancer Weekly (2008-06-17)
|
